Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.53 |
| ▸ | CSF1R | P07333 | 7/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515271 | 0.92 | PDGFRB (0.54) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4501673 | 0.86 | PDGFRB (0.56) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL5009418 | 0.80 | KDR (0.56) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4513331 | 0.80 | PDGFRB (0.60) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4498690 | 0.79 | KDR (0.53) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4514154 | 0.78 | KDR (0.52) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4502654 | 0.78 | PDGFRB (0.58) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4168601 | 0.78 | PDGFRB (0.57) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4503422 | 0.78 | PDGFRB (0.80) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4505823 | 0.77 | PDGFRB (0.78) | PDGFRBCSF1RKDRFLT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | PDGFRB 1820/4885CSF1R 588/4885KDR 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.